Effects of Psilocybin in Anorexia Nervosa

Brief Summary

This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.

Intervention / Treatment

  • Drug: Psilocybin

Condition or Disease

  • Anorexia Nervosa

Phase

Study Design

Study type: Interventional
Status: Recruiting
Study results: No Results Available
Age: 18 Years to 65 Years   (Adult, Older Adult)
Enrollment: 18 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Aug 26, 2019
Primary Completion: Dec 01, 2022
Completion Date: Dec 01, 2022
Study First Posted: Aug 12, 2019
Results First Posted: Aug 30, 2020
Last Updated: Oct 26, 2021

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 65

This clinical trial is recruiting

Are you interested in participating in this trial or others? We'd love to help.

More Details

NCT Number: NCT04052568
Other IDs: IRB00182516
Study URL: https://ClinicalTrials.gov/show/NCT04052568
Last updated: Jun 16, 2022